Key takeaways

  • Hormonal birth control (combined pills, patch, ring, hormonal IUS, injection, implant) is linked to a small relative rise in breast cancer risk during use — roughly 1 extra case per 7,690 women per year — that returns to baseline within 5 to 10 years of stopping.
  • Long-term combined pill use slightly raises cervical cancer risk only in women with persistent HPV infection; HPV vaccination and regular screening matter far more than your contraceptive choice.
  • Combined pills cut ovarian cancer risk by about 30 to 50 percent and endometrial cancer risk by a similar amount, with protection lasting decades after you stop.
  • The copper IUD has no proven link to any cancer, making it the cleanest option for women avoiding hormones for cancer-related reasons.
  • For most average-risk women the lifetime cancer effect of using hormonal contraception is roughly neutral; cancer risk is one input among many, not usually the deciding one.
  • Women with current or recent breast cancer, a BRCA mutation, or strong family history need individualised counselling — not a blanket yes or no.

How hormones interact with cancer biology

To make sense of the data, it helps to understand why sex hormones affect cancer risk at all. Three simple ideas explain most of it.

Oestrogen and progesterone drive growth in hormone-sensitive tissues. The breast, the lining of the uterus (endometrium), the cervix, and the ovary surface all respond to circulating hormones. Different contraceptives change this hormonal environment in different ways — combined pills supply steady low-dose synthetic oestrogen plus a progestin and switch off your own ovulation; the hormonal IUS releases progestin mainly to the uterine lining with very little reaching the bloodstream; the injection and implant give progestin without oestrogen. Each method's cancer pattern reflects how it changes growth in each at-risk tissue. If you want the basics of how the pill works, see oral contraceptives explained.

The same growth signal protects some tissues and slightly stresses others. In the breast, sustained hormone exposure modestly raises the chance of harmful changes in vulnerable cells. In the endometrium, the steady progestin in pills and the hormonal IUS prevents the unopposed-oestrogen state that drives cancer, so risk drops. In the ovary, switching off ovulation reduces the repeated surface injuries thought to seed some cancers, so risk drops there too.

Risk during use is not the same as lifetime risk. For breast and cervical cancer the small extra risk applies only while you use the method and fades within 5 to 10 years of stopping. For ovarian and endometrial cancer the protection lasts for decades. Over a whole lifetime, the net effect for an average-risk woman is often neutral or slightly favourable.

Absolute numbers matter more than percentages. A 20 percent relative rise in breast cancer risk sounds alarming but works out to about 1 extra case per 7,690 women per year of use (Mørch et al, New England Journal of Medicine, 2017). For a woman in her 20s, whose baseline risk is low, 20 percent more of a small number is still small. This is why ACOG, FOGSI, NICE, and WHO do not treat cancer risk as a reason to avoid the pill in average-risk women, while still recommending an individual conversation for women with specific risk factors.

Combined hormonal contraception and breast cancer

The breast cancer link is the most studied and most talked-about question in contraception research. The direction is clear and the size is modest.

The headline finding. Combined methods — the pill, the contraceptive patch, and the vaginal ring — carry a small relative rise in breast cancer during use that returns to baseline within 5 to 10 years of stopping. The largest study, a Danish national cohort of 1.8 million women followed for nearly 11 years (Mørch et al, 2017), found a relative risk of 1.20 for current or recent users versus never-users — covering combined methods like the contraceptive patch and the vaginal ring as well as the pill. That is about one extra case per 7,690 women using hormonal contraception for a year.

Duration matters. Risk was higher with longer use — rising from 1.09 with under a year of use to 1.38 with more than 10 years of continuous use. The older Collaborative Group pooled analysis (Lancet, 1996), covering more than 53,000 breast cancer cases, found the same pattern of modest elevation during use that faded after stopping.

It reverses after you stop. By 10 years after stopping, former users have the same breast cancer risk as women who never used it. The elevated risk is a temporary effect of hormone exposure, not a permanent change.

Progestin-only methods are not automatically safer. The injection, implant, progestin-only pills, and the hormonal IUS also show a small breast-cancer rise during use — broadly similar in size to combined pills despite having no oestrogen. The hormonal IUS shows the smallest effect because so little hormone reaches the bloodstream. This updated previous teaching that progestin-only equals lower breast risk.

Family history and BRCA. Women with strong family history or a known BRCA1/BRCA2 mutation have a higher baseline, so the same relative rise translates to a larger absolute increase. Combined pills are not banned by family history alone, but the conversation is more detailed — and the pill's strong ovarian-cancer protection is especially relevant for BRCA1 carriers. If testing is on your mind, see BRCA testing in India.

Current or recent breast cancer. Combined hormonal contraception is contraindicated in women with current breast cancer or breast cancer in the past 5 years (WHO MEC Category 4). The copper IUD is the appropriate hormone-free choice. Decisions for women more than 5 years out are made jointly with the oncologist.

Indian context. Breast cancer is now the most common cancer in Indian women, with rising urban incidence tracked by ICMR's National Cancer Registry Programme. Rates in Indian metro registries (around 25 to 40 per 100,000) remain lower than in Western countries but are climbing. FOGSI guidance allows combined pills for women without a family history using standard counselling, and recommends individual assessment — including breast cancer screening and oncology referral where appropriate — for those with significant family history.

Combined pills and cervical cancer

The cervical cancer link is real but conditional: it depends on persistent HPV infection, and HPV — not the pill — is the necessary cause of cervical cancer.

The headline finding. Long-term combined pill use (5 years or more) is linked to a small relative rise in cervical cancer in women with persistent HPV. The IARC 2007 review of 24 studies (over 16,500 women with cervical cancer) found relative risk of about 1.1 under 5 years of use, 1.6 at 5 to 9 years, and 1.9 at 10 or more years of current use. The risk falls after stopping and returns to baseline roughly 10 years later.

Why it happens. The pill does not cause HPV, which is sexually transmitted, and HPV is needed for cervical cancer to develop at all. Hormones appear to influence how the cervix responds to HPV. Whatever the exact mechanism, the effect applies only to HPV-positive women and is small in absolute terms. Learn the basics in our overview of HPV types, symptoms, and treatment.

Vaccination changes everything. HPV vaccination dramatically reduces high-risk HPV infection, pre-cancer, and cervical cancer. India's indigenously developed Cervavac (Serum Institute) launched in 2022, and HPV vaccination is being rolled into public adolescent immunisation. For a vaccinated woman, any small pill-related risk applies to a much smaller baseline. See our guide to the HPV vaccine in India.

Screening is the foundation. Whether or not you use the pill, cervical screening is the core of prevention. WHO recommends HPV testing every 5 to 10 years for women aged 30 to 65 (or a Pap every 3 years where HPV testing is unavailable). Visual inspection (VIA) is offered at many primary health centres; HPV testing and Pap smears are available privately. Our explainer on cervical cancer screening walks through the options and what to expect.

The management point. For women on the pill, the right response to this small risk is regular screening — not avoiding the method. Screening catches pre-cancer changes when they are easily treated. For women with persistent high-risk HPV or significant cervical dysplasia, a gynaecologist may discuss switching to a non-hormonal method — an individual decision.

Combined pills substantially reduce ovarian cancer risk

The protective effect on ovarian cancer is one of the major benefits of the pill — large, durable across decades, and seen even in high-risk women including BRCA carriers.

The headline finding. Combined hormonal contraception reduces lifetime risk of epithelial ovarian cancer by roughly 30 to 50 percent with 5 or more years of use. The Collaborative Group pooled analysis (Lancet, 2008), covering more than 23,000 ovarian cancer cases across 21 countries, found relative risk of 0.73 for ever-use, falling further with duration — 0.64 at 5 to 9 years and 0.42 with 15 or more years of cumulative use.

It lasts. The protection persists for decades after stopping — still about a 15 percent reduction 10 years after the last pill, and similar protection 20 to 29 years later. A temporary intervention with a lasting benefit. To understand more about the disease itself, see ovarian cancer symptoms in Indian women.

Why it happens. Combined pills switch off ovulation. Each ovulation creates a tiny wound in the ovarian surface that has to heal, and this repeated injury-and-repair is thought to seed some ovarian cancers. Fewer ovulations across your reproductive years means fewer of these events — the same reason pregnancy and breastfeeding also lower risk.

The absolute numbers. Ovarian cancer is uncommon but lethal — Indian incidence around 5 to 9 per 100,000, lifetime risk around 1 percent in the general population and far higher in BRCA carriers (around 40 to 50 percent in BRCA1). A 30 to 50 percent reduction in that risk is meaningful.

BRCA carriers. Combined pills give similar relative reductions in this group. For BRCA1 carriers in particular, where ovarian cancer is a dominant concern, the protective effect is a real benefit to weigh alongside the breast-cancer discussion. Many BRCA1 carriers use combined pills in their 20s and 30s as a bridge to risk-reducing surgery in the early 40s. These decisions are made with a genetic counsellor and gynaecological oncologist.

Which methods protect. Methods that suppress ovulation (the implant, the injection) likely give some ovarian protection, though the evidence is smaller. The hormonal IUS does not reliably stop ovulation, so its ovarian effect is weaker. The copper IUD does not suppress ovulation and offers no ovarian protection.

Pills, the hormonal IUS, and endometrial cancer protection

Endometrial (uterine lining) cancer is the second area where hormonal contraception offers strong, lasting protection.

The headline finding. Combined pills cut lifetime endometrial cancer risk by roughly 30 to 50 percent. The Collaborative Group analysis (Lancet Oncology, 2015), covering more than 27,000 cases, found every 5 years of use was linked to relative risk of 0.76 — so 5 years cuts risk about 24 percent and 10 years about 43 percent. The protection lasts at least 30 years after stopping.

Why it happens. Endometrial cancer is largely driven by oestrogen acting on the lining without enough progestin to balance it — the situation in anovulatory cycles, PCOS, and the perimenopausal years. Combined pills supply a steady progestin every day, keeping the lining thin and quiet, which is strongly protective. Knowing the warning signs of endometrial cancer is still worthwhile regardless of contraception.

The hormonal IUS is especially protective. The levonorgestrel IUS delivers progestin directly to the lining, producing a thin, atrophic endometrium. The protection is so strong that the device is used therapeutically to treat endometrial hyperplasia and, in selected fertility-sparing cases under oncology supervision, early endometrial cancer.

Women with PCOS. PCOS raises endometrial cancer risk through chronic anovulation and unopposed oestrogen. Combined pills (or the hormonal IUS, or cyclical progestin) are first-line for endometrial protection in women with PCOS who are not currently trying to conceive — see PCOS treatment options.

Lynch syndrome. Women with Lynch syndrome carry a 40 to 60 percent lifetime endometrial cancer risk. Combined pills or the hormonal IUS are recommended as part of risk reduction until risk-reducing hysterectomy, usually in the early 40s after childbearing.

Indian context. Endometrial cancer is rising in India alongside obesity, diabetes, PCOS, and later, fewer pregnancies. The protective effect of pills and the hormonal IUS is increasingly relevant, and is reflected in FOGSI and Indian Society of Gynaecological Oncology guidance.

The hormonal IUS and cancer risk

The levonorgestrel IUS (Mirena and Kyleena in India) has a mixed profile — like combined pills in some ways, importantly different in others.

  • Breast cancer: a small relative rise during use (around 1.2), similar in size to combined pills, presumed to come from low-level systemic absorption. The effect returns to baseline after removal.
  • Cervical cancer: less clear than for combined pills; some studies show no increase. Screening is recommended for all sexually active women regardless of method.
  • Ovarian cancer: weaker protection than combined pills because the IUS does not reliably stop ovulation.
  • Endometrial cancer: strong protection — the lining becomes thin and atrophic, and the device is used therapeutically for hyperplasia.

The practical balance. The hormonal IUS gives 5 to 8 years of highly effective contraception, dramatically lighter periods (often none at all), relief of painful periods, and powerful endometrial protection. The small breast-cancer effect is the main cancer-related consideration, and for most women the net benefit is clearly positive. Women with elevated breast cancer risk should have an individual discussion. Our side-by-side comparison of the copper IUD versus Mirena covers how to choose.

Indian access. Mirena is available at private gynaecology OPDs for roughly Rs 12,000 to 25,000 including insertion; Kyleena is similar but less commonly stocked. The hormonal IUS is not yet part of the national family planning programme, though FPAI and Marie Stopes offer it at subsidised rates in some centres.

The injection, implant, and progestin-only pills

Progestin-only methods broadly parallel combined contraception for some cancers and differ for others.

The injection (DMPA). Available in India as Antara through the national programme since 2017, and privately as Depo-Provera. Given once every 3 months. Its breast-cancer profile is similar to combined pills — a small rise during use that returns to baseline. It suppresses ovulation, so it offers ovarian protection, and it thins the lining over time, so it offers endometrial protection. Some studies suggest a small cervical-cancer rise with long-term use, like combined pills. See our overview of the contraceptive injection in India.

The implant. The etonogestrel arm implant gives 3 years of contraception. The cancer evidence base is smaller but likely resembles other progestin-only methods — a small breast effect, with probable ovarian and endometrial protection.

Progestin-only pills. Less commonly used in India than combined pills. The evidence is limited but points to a pattern similar to other hormonal methods.

The big-picture point. The hormone-free copper IUD remains the cleanest option from a cancer perspective — no link to any cancer. Every hormonal method shares a small breast-cancer rise during use, with varied profiles for the other cancers. The choice between methods usually turns on effectiveness, side effects, bleeding patterns, hormone preferences, cost, and convenience. Cancer risk is one input, rarely the dominant one. If you prefer to avoid hormones entirely, see non-hormonal birth control in India.

The copper IUD: no cancer association

The copper IUD stands apart because it has no demonstrated link to any cancer. Its action is non-hormonal — copper ions create an environment hostile to sperm — with no systemic metabolic effect, and large studies consistently show no association with breast, cervical, ovarian, or endometrial cancer.

  • Breast cancer: no association. Fully suitable for women with a personal history of breast cancer (WHO MEC Category 1), strong family history, or a BRCA mutation.
  • Cervical cancer: no association. Some data hint at a small protective effect, but the key point is the absence of any rise.
  • Ovarian cancer: no association, and no protection (it does not suppress ovulation).
  • Endometrial cancer: possibly a small protective effect, but weaker evidence than for hormonal methods.

The practical balance. The copper IUD is the method most often chosen by women specifically avoiding hormones for cancer reasons, by those with current or past hormone-sensitive cancers, and by those who prefer a metabolically neutral option. The trade-off is heavier, crampier periods in some women. Full detail is in our guide to copper IUDs.

Indian access. Free at any PHC, CHC, or district hospital under the national family planning programme, subsidised at FPAI and Marie Stopes, and around Rs 500 to 3,000 at private gynaecology OPDs. The Cu-T 380A is the standard device and lasts 10 years.

Special situations: BRCA, family history, survivors

Some situations need an individual conversation that goes beyond population averages.

BRCA1 or BRCA2 carriers. These women have a substantially higher baseline breast and ovarian cancer risk. Combined pills modestly raise breast risk during use but substantially lower ovarian risk long-term, so the net effect depends on the specific mutation, age, duration, and planned surgeries. NCCN, the Indian Society of Gynaecological Oncology, and FOGSI all recommend individualised counselling. Many BRCA1 carriers do use combined pills in their 20s and 30s for the ovarian protection; the copper IUD avoids the question for those who prefer it.

Strong family history without a known mutation. One affected first-degree relative roughly doubles personal risk. Combined pills can be prescribed with explicit counselling and a discussion of screening; BRCA testing should be offered where the family pattern suggests it. Non-hormonal options are equally valid.

Current or recent breast cancer. Combined hormonal contraception is contraindicated (WHO MEC Category 4 for current disease; Category 3 for past disease). The copper IUD is the appropriate choice (Category 1), with decisions made jointly with the oncologist.

PCOS, obesity, diabetes, Lynch syndrome. These groups have a substantially higher endometrial cancer risk, so combined pills or the hormonal IUS are recommended for protection. The copper IUD does not provide adequate endometrial protection here.

Approaching menopause. Combined pills are generally avoided in women over 35 who smoke or who have hypertension, migraine with aura, or clotting risk factors. For others, they can continue until menopause for contraception and cycle control; the hormonal IUS, copper IUD, and progestin-only methods are alternatives. Our guide to contraception in perimenopause covers the choices.

Indian context. Specialist counselling is concentrated at tertiary centres such as AIIMS, Tata Memorial, and the Cancer Institute (Adyar). For women in smaller cities, primary gynaecology consultation with tele-referral is increasingly available through teleconsult platforms.

When to see a doctor

  • A new breast lump, thickening, skin dimpling, nipple change, or bloody nipple discharge
  • Bleeding between periods, after sex, or any bleeding after menopause
  • Unusual, persistent, or foul-smelling vaginal discharge
  • Persistent bloating, early fullness, pelvic or abdominal pain, or change in bowel or bladder habits lasting more than two to three weeks
  • An abnormal Pap or HPV test result, or a screening you have been putting off
  • A strong family history of breast or ovarian cancer (multiple relatives, early-onset disease, or known BRCA mutation) before starting a hormonal method
  • A personal history of hormone-sensitive cancer — discuss contraception with both your gynaecologist and oncologist

Putting the cancer-risk discussion in perspective

This topic often generates more anxiety than the evidence warrants. A few framings help.

The absolute numbers are small. A 20 percent relative rise in breast cancer during pill use is about 1 extra case per 7,690 women per year. For a woman in her 20s this is a vanishingly small absolute number — and the risks of an unintended pregnancy without effective contraception are far larger.

The net effect is often neutral or positive. Combined pills modestly raise breast and cervical risk during use and substantially lower ovarian and endometrial risk for decades. For the average woman who uses pills for 5 to 10 years in her 20s and 30s, the integrated lifetime cancer effect is often close to neutral or slightly favourable.

The risks reverse; the benefits persist. The breast and cervical rise returns to baseline within 5 to 10 years of stopping, while the ovarian and endometrial protection lasts for decades. That asymmetry is in your favour.

Cancer prevention is multifactorial. The strongest levers for Indian women are HPV vaccination, regular cervical screening from age 30, breast awareness and screening, maintaining a healthy weight, staying active, limiting alcohol, not smoking, and managing conditions like diabetes. Contraceptive choice is one input among many.

The decision is yours. FOGSI, ACOG, NICE, and WHO all emphasise informed choice — the clinician's job is to give you accurate information and support your decision, not override it. Quality counselling is available at FPAI clinics, Marie Stopes, government gynaecology OPDs, and private practices across India.

Myths vs facts

Frequently asked questions

Does the pill increase breast cancer risk?

Slightly, and only while you use it. Large studies show a roughly 20 percent relative rise during use — about 1 extra case per 7,690 women per year — that returns to baseline within 5 to 10 years of stopping. For young women with a low baseline, the absolute increase is very small.

Which birth control has the lowest cancer risk?

The copper IUD has no proven link to any cancer because it contains no hormones. It is often chosen by women avoiding hormones for cancer-related reasons. Among hormonal methods, the difference in breast-cancer effect is small, while combined pills add meaningful ovarian and endometrial protection.

Does birth control protect against any cancers?

Yes. Combined pills reduce ovarian cancer risk by about 30 to 50 percent and endometrial cancer risk by a similar amount, with protection lasting for decades after stopping. The hormonal IUS is especially protective against endometrial cancer.

Can I use the pill if breast cancer runs in my family?

Often yes, but it needs an individual conversation. Family history raises your baseline, so the small relative rise becomes a slightly larger absolute one. ACOG, FOGSI, and NCCN recommend individualised counselling, BRCA testing where the family pattern suggests it, and discussion of non-hormonal alternatives like the copper IUD.

Does the pill cause cervical cancer?

No. HPV — a sexually transmitted infection — is the necessary cause of cervical cancer. Long-term pill use slightly raises risk only in women with persistent HPV. HPV vaccination and regular cervical screening matter far more than your choice of contraception.

If I stop hormonal birth control, does my cancer risk go back to normal?

For breast and cervical cancer, yes — the small extra risk fades within 5 to 10 years of stopping. The protective effects on ovarian and endometrial cancer, however, continue for decades after you stop.

Sources